Galmed Pharmaceuticals Ltd (GLMD) Expected to Post Quarterly Sales of $300,000.00

Share on StockTwits

Equities research analysts predict that Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) will report $300,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Galmed Pharmaceuticals’ earnings. Galmed Pharmaceuticals posted sales of $270,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 11.1%. The business is scheduled to announce its next quarterly earnings results on Thursday, November 8th.

According to Zacks, analysts expect that Galmed Pharmaceuticals will report full year sales of $730,000.00 for the current year, with estimates ranging from $540,000.00 to $1.14 million. For the next fiscal year, analysts expect that the firm will report sales of $600,000.00 per share. Zacks’ sales calculations are an average based on a survey of research firms that cover Galmed Pharmaceuticals.

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). Galmed Pharmaceuticals had a negative net margin of 1,072.44% and a negative return on equity of 36.66%. The firm had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.27 million.

A number of analysts recently commented on GLMD shares. Cantor Fitzgerald assumed coverage on Galmed Pharmaceuticals in a research report on Wednesday, July 11th. They issued a “buy” rating and a $59.00 target price for the company. ValuEngine raised Galmed Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 12th. Maxim Group decreased their price objective on Galmed Pharmaceuticals from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, August 2nd. Zacks Investment Research lowered Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 8th. Finally, SunTrust Banks boosted their price objective on Galmed Pharmaceuticals from $15.00 to $31.00 in a report on Tuesday, June 12th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $34.40.

A number of institutional investors and hedge funds have recently modified their holdings of GLMD. Deutsche Bank AG bought a new stake in Galmed Pharmaceuticals during the 4th quarter worth approximately $246,000. UBS Group AG boosted its stake in shares of Galmed Pharmaceuticals by 5,334.8% in the 1st quarter. UBS Group AG now owns 40,000 shares of the biopharmaceutical company’s stock worth $223,000 after buying an additional 39,264 shares during the last quarter. A.R.T. Advisors LLC purchased a new position in shares of Galmed Pharmaceuticals in the 1st quarter worth approximately $107,000. Park West Asset Management LLC boosted its stake in shares of Galmed Pharmaceuticals by 24.2% in the 1st quarter. Park West Asset Management LLC now owns 363,700 shares of the biopharmaceutical company’s stock worth $2,026,000 after buying an additional 70,853 shares during the last quarter. Finally, FNY Investment Advisers LLC purchased a new position in shares of Galmed Pharmaceuticals in the 2nd quarter worth approximately $333,000. 55.77% of the stock is owned by hedge funds and other institutional investors.

Shares of Galmed Pharmaceuticals stock opened at $13.00 on Friday. Galmed Pharmaceuticals has a one year low of $3.61 and a one year high of $27.06.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.

Featured Story: Stop Order Uses For Individual Investors

Get a free copy of the Zacks research report on Galmed Pharmaceuticals (GLMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply